Loading company…
Mormil is developing a drug discovery platform that studies molecular movement using chemical sensing and NMR.
Founded in 2022 and based in Japan, Mormil develops a drug discovery platform combining chemical sensing with nuclear magnetic resonance (NMR) to detect molecular movement and condition. In April 2026, the company raised JPY 300 million in Series A funding from BP Capital, Nanto Capital Partners, Higin Capital, UntroD Capital, Mitsubishi UFJ Capital, and Senshu Ikeda Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in